Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Номзүйн дэлгэрэнгүй
Үндсэн зохиолчид:	Moran, A, Ramakrishnan, S, Borg, C, Connolly, C, Couillard, S, Mwasuku, C, Pavord, I, Hinks, T, Lehtimaki, L
Формат:	Conference item
Хэл сонгох:	English
Хэвлэсэн:	European Respiratory Society 2020

Ижил төстэй зүйлс

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
-н: Moran, AM, зэрэг
Хэвлэсэн: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
-н: Shrimanker, R, зэрэг
Хэвлэсэн: (2017)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
-н: Charlene Desaintjean, зэрэг
Хэвлэсэн: (2024-03-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
-н: Bel, E, зэрэг
Хэвлэсэн: (2014)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
-н: Andrea Portacci, зэрэг
Хэвлэсэн: (2023-10-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
-н: Bel, E, зэрэг
Хэвлэсэн: (2014)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
-н: S. K. Zyryanov, зэрэг
Хэвлэсэн: (2020-12-01)

Mepolizumab in refractory eosinophilic asthma.
-н: Pavord, I, зэрэг
Хэвлэсэн: (2010)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
-н: Arian Ghassemian, зэрэг
Хэвлэсэн: (2021-01-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
-н: Pavord, I
Хэвлэсэн: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
-н: Haldar, P, зэрэг
Хэвлэсэн: (2009)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
-н: Howell, I, зэрэг
Хэвлэсэн: (2024)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
-н: Erminia Ridolo, зэрэг
Хэвлэсэн: (2020-10-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
-н: Kayser MZ, зэрэг
Хэвлэсэн: (2021-07-01)

Mepolizumab treatment in patients with severe eosinophilic asthma.
-н: Ortega, H, зэрэг
Хэвлэсэн: (2014)

Mepolizumab for eosinophilic COPD
-н: Sciurba, F, зэрэг
Хэвлэсэн: (2018)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
-н: Osamu Matsuno, зэрэг
Хэвлэсэн: (2019-01-01)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
-н: Yancey, S, зэрэг
Хэвлэсэн: (2016)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
-н: Menzella F, зэрэг
Хэвлэсэн: (2016-06-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
-н: Mirhojjat Khorasanizadeh, зэрэг
Хэвлэсэн: (2017-07-01)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
-н: Gómez-Bastero Fernández A, зэрэг
Хэвлэсэн: (2022-05-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
-н: Gunsoy, N, зэрэг
Хэвлэсэн: (2017)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
-н: Laura J. Walsh, зэрэг
Хэвлэсэн: (2023-01-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
-н: Alistair Cook, зэрэг
Хэвлэсэн: (2021-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
-н: Howell, I, зэрэг
Хэвлэсэн: (2024)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
-н: Imran Howell, зэрэг
Хэвлэсэн: (2024-07-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
-н: Stephen G. Noorduyn, зэрэг
Хэвлэсэн: (2021-12-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
-н: Francesco Menzella, зэрэг
Хэвлэсэн: (2016-12-01)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
-н: Couillard, S, зэрэг
Хэвлэсэн: (2021)

Asthma in pregnancy: An update
-н: Couillard, S, зэрэг
Хэвлэсэн: (2020)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
-н: Shrimanker, R, зэрэг
Хэвлэсэн: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
-н: Ortega, H, зэрэг
Хэвлэсэн: (2016)

Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
-н: Gittins, A, зэрэг
Хэвлэсэн: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
-н: Steven W. Yancey, зэрэг
Хэвлэсэн: (2019-09-01)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
-н: Lisha Li, зэрэг
Хэвлэсэн: (2021-06-01)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
-н: Kohei Somekawa, зэрэг
Хэвлэсэн: (2024-12-01)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
-н: Andrew Menzies-Gow, зэрэг
Хэвлэсэн: (2019-09-01)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
-н: Shrimanker, R, зэрэг
Хэвлэсэн: (2018)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
-н: Oliver, ME, зэрэг
Хэвлэсэн: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
-н: Carlos Martínez-Rivera, зэрэг
Хэвлэсэн: (2021-01-01)